Last reviewed · How we verify
NCT02563197
Inhalation Flow Rate-study
Phase 1 trial testing T-326 Inhaler in Bronchiectasis in 33 participants. Completed in 29 April 2016.
17 February 2016
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 23 November 2015 |
| Primary completion | 17 February 2016 |
| Estimated completion | 29 April 2016 |
| Sites | 10 locations across Germany |
Drugs / interventions tested
- T-326 Inhaler
Conditions studied
- Bronchiectasis — all drugs for Bronchiectasis →
Sponsor
Bayer — full company profile →
Who can join
18 and older, any sex, with Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02563197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bronchiectasis
Currently open trials in the same condition.
- NCT07283497 — Itraconazole Therapy In Bronchiectasis With Airway Mold · Phase 4 · recruiting
- NCT07188675 — Functional Inspiratory Training in Bronchiectasis · NA · recruiting
- NCT06897761 — Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children Wit · NA · recruiting
- NCT07147803 — Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis · active not recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02563197 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 26 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02563197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing